Effect of Infrared-Assisted Intravenous Catheterization on Patient Comfort in Lung Cancer Patients
Effect of Infrared-Assisted Intravenous Catheterization on Patient Comfort in Lung Cancer Patients: A Mixed-Methods Study
This study evaluated the effect of near-infrared (NIR) vein visualization-assisted peripheral intravenous catheterization on procedure-specific patient comfort and procedural pain in adults with lung cancer receiving outpatient chemotherapy.
Patients receiving chemotherapy often develop progressive venous damage, which can make peripheral intravenous catheterization difficult. Failed attempts may increase pain and discomfort.
The study used an explanatory sequential mixed-methods design (QUAN→qual). In the quantitative phase, 160 patients were randomized 1:1 to NIR-assisted catheterization or to standard catheterization based on visual inspection and palpation. In the qualitative phase, semi-structured individual interviews were conducted with 11 patients from the intervention group to explore their experiences with the NIR device.
The study was conducted at the Outpatient Chemotherapy Unit of Ataturk University Research Hospital, Erzurum, Turkey, as part of a doctoral thesis in Fundamentals of Nursing.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
BACKGROUND:
Peripheral intravenous catheterization (PIVC) is one of the most common invasive procedures in clinical practice. In patients receiving chemotherapy, repeated venous access and chemotherapy-related vascular damage can make catheterization difficult and can increase the number of attempts, pain and discomfort. Near-infrared (NIR) vein visualization devices project a real-time map of superficial veins onto the skin and may help the nurse select a suitable vein.
STUDY DESIGN:
Explanatory sequential mixed-methods design (QUAN→qual). The sequential nature of the design was established at the level of analysis and integration. Because patients in the outpatient unit could not easily be reached again after treatment, qualitative interviews were conducted during the same period as quantitative data collection; qualitative analysis and integration were performed after the quantitative analysis was completed. The trial is reported according to CONSORT 2025, the qualitative component according to COREQ and the mixed-methods integration according to GRAMMS.
Phase 1 (Quantitative): Single-centre, parallel-group (1:1), two-arm, open-label randomized controlled trial.
- Intervention group (80 randomized): PIVC assisted by an NIR vein visualization device.
- Control group (80 randomized): PIVC using the unit's routine method (visual inspection and palpation) without any technological assistance.
- Both groups followed the same standard procedure with consumables from a single brand and lot group. A maximum of three attempts was allowed.
Phase 2 (Qualitative): Qualitative descriptive design. Semi-structured individual interviews were conducted with 11 purposively selected patients from the intervention group after the T2 measurements. Interviews were audio recorded, transcribed verbatim and analysed with hybrid (deductive and inductive) qualitative content analysis. Coding was performed independently by the researcher and the thesis supervisor. Adequacy of the qualitative sample was assessed with the information power criterion. (The initial protocol planned a phenomenological approach with 15-20 patients.)
PRACTITIONERS:
The initial protocol planned a single practitioner nurse. Because this was not feasible given the patient volume and task distribution of the unit, catheterizations were performed by the unit nurses within their routine weekly rotation. All 7 nurses received the same structured device training and completed a clinical run-in period of at least two weeks before data collection. All had at least five years of experience with the conventional method (mean 13.57 years, range 9-18). Because randomization was performed at the patient level, each nurse performed procedures in both groups.
RANDOMIZATION AND ALLOCATION CONCEALMENT:
A computer-generated randomization list in blocks of four (Research Randomizer, www.randomizer.org) was prepared by the thesis researcher, who was not involved in the clinical conduct of the study. After eligibility was confirmed, informed consent was obtained and baseline measurements were completed, the data collector obtained the group allocation by telephone from the researcher holding the list and informed the practitioner nurse (central telephone allocation).
MASKING:
This was an open-label trial. Masking of patients and practitioner nurses was not possible because the NIR device projects visible light onto the skin. All data (T0, T1 and T2) were collected by the same trained data collector, who learned the group allocation before the procedure and was therefore not blinded. To limit measurement bias, structured observation forms, predefined operational criteria and standard written instructions for each measurement tool were used. Statistical analyses were performed with group labels visible.
SAMPLE SIZE:
Calculated with G*Power 3.1.9.7 for the primary outcome (PIVCCS) (two-sided alpha = 0.05, power = 0.80, Cohen's d = 0.50): a minimum of 64 patients per group, increased to 80 per group (160 in total) to allow for 20% attrition. All 160 patients were randomized. After randomization, 30 patients (18.75%; 15 per group) were removed because of voluntary withdrawal, duplicate records or incomplete forms, and 130 patients (65 per group) were included in the modified intention-to-treat analysis.
DATA COLLECTION TIMEPOINTS:
T0 (before the procedure): patient information form, baseline pain (VAS) and Adult Difficult Intravenous Access (A-DIVA) score.
T1 (during the procedure): first-attempt success, total number of attempts, total procedure duration (from tourniquet application to successful fixation of the catheter, in seconds), catheter size and site, and complications (hematoma, extravasation, adverse events).
T2 (after the procedure; starting 5 minutes after the patient returned to the treatment chair and before the chemotherapy infusion): procedural pain (VAS) and Peripheral Intravenous Catheterization Comfort Scale (PIVCCS).
STATISTICAL ANALYSIS:
Quantitative data were analysed with jamovi (version 2.7.16) in the modified intention-to-treat set (n=130); significance was set at p < 0.05. Normality was assessed with the Kolmogorov-Smirnov test. Because the outcome variables were not normally distributed, between-group comparisons used the Mann-Whitney U test (effect size: rank-biserial correlation), within-group comparison of pre- and post-procedure pain used the Wilcoxon signed-rank test, and categorical variables were compared with Pearson's chi-square test or Fisher's exact test. Baseline balance was assessed with standardized differences. Supplementary adjusted analyses used ANCOVA (covariates: A-DIVA score and baseline VAS), with rank-based ANCOVA as a robustness check. Subgroup analyses by A-DIVA risk category were exploratory. Relationships between variables were examined with Spearman's rank correlation. Internal consistency of the PIVCCS was assessed with Cronbach's alpha and floor/ceiling effects with the 15% criterion.
Qualitative data were analysed with hybrid qualitative content analysis, and the two datasets were integrated with a joint display table.
HYPOTHESES:
H1: Procedure-specific comfort (PIVCCS) scores are higher with NIR-assisted catheterization than with the standard method.
H2: First-attempt success is higher, and the number of attempts and procedure duration are lower, with NIR-assisted catheterization.
H3: Post-procedure pain (VAS) is lower with NIR-assisted catheterization. H4: Procedure-related complications (hematoma, extravasation, adverse events) are less frequent with NIR-assisted catheterization.
The qualitative phase did not test hypotheses; its research question was: How do patients with lung cancer describe their experience of NIR-assisted intravenous catheterization?
CHANGES TO THE REGISTERED OUTCOMES:
Following the doctoral thesis committee review (September 2026), this record was updated to match the final analysis reported in the thesis: (1) the Trust in Nurses Scale, registered as a primary outcome, was excluded from the analysis because it showed insufficient internal consistency (Cronbach's alpha = 0.227) and a marked ceiling effect (57.7%) in this sample; (2) procedure-specific comfort (PIVCCS) is the sole primary outcome and post-procedure pain (VAS) is reported as a secondary outcome; (3) first-attempt success, number of attempts, procedure duration and complications, which were recorded at T1 as planned, were added as secondary outcomes; (4) the masking and allocation descriptions were corrected to reflect the actual conduct of the study (open label; no masking of any role).
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
Erzurum
-
Erzurum、Erzurum、トルコ(Türkiye)、25100
- Ataturk University Research Hospital
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Aged 18 years or older
- Histopathologically confirmed lung cancer (small cell or non-small cell)
- Receiving active systemic chemotherapy (at least one cycle completed)
- Indication for a peripheral intravenous catheter for chemotherapy administration
- Able to speak and understand Turkish sufficiently to communicate
- Read and signed the informed consent form
Exclusion Criteria:
- Situations requiring emergency or life-saving catheterization
- Presence of a central venous catheter (port, PICC or tunneled catheter)
- Anatomical anomaly, amputation, post-mastectomy lymphedema or arteriovenous fistula in both upper extremities
- Active local infection, dermatitis or impaired skin integrity at the planned catheterization site
- Altered consciousness or disorientation
- Mediastinal, supraclavicular or infraclavicular mass/lymphadenopathy that may affect upper extremity venous return
Withdrawal Criteria:
- Withdrawal of consent at any stage
- Need for an off-protocol intervention (decision for central access after failure at the third attempt)
- Development of an acute clinical condition preventing completion of data collection
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:NIR-Assisted Catheterization Group
Participants (n=80 randomized) received peripheral intravenous catheterization assisted by a near-infrared (NIR) vein visualization device. After tourniquet application and skin antisepsis, the device was held about 20-30 cm above the insertion site and the vein map projected onto the skin was used to select the vein; the device remained active during catheter advancement. Procedures were performed by the trained unit nurses (7 nurses in routine rotation, all with the same device training and a run-in period). Maximum 3 attempts allowed. |
A near-infrared (NIR) vein visualization device was used to assist peripheral intravenous catheterization. The device uses near-infrared light (700-950 nm), which is absorbed more by hemoglobin than by the surrounding tissue, and projects a real-time map of superficial veins onto the skin. After tourniquet application and skin antisepsis, the device was positioned about 20-30 cm above the insertion site; the nurse used the projected image to assess the course, branching and diameter of the veins and to select the most suitable vein. The device was kept active during catheter advancement.
他の名前:
|
|
アクティブコンパレータ:Standard Catheterization Group
Participants (n=80 randomized) received peripheral intravenous catheterization using the unit's routine method of visual inspection and palpation, without any technological assistance (no NIR, ultrasound or transillumination). The same standard procedure and consumables as in the experimental group were used. Procedures were performed by the same trained unit nurses as in the experimental group (patient-level randomization). Maximum 3 attempts allowed. |
Standard peripheral intravenous catheterization performed using conventional palpation and visual inspection technique without any technological assistance. The nurse identifies the vein by touch and visual assessment, applies a tourniquet, and inserts the catheter based on clinical experience. This represents the current standard of care in most clinical settings. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Procedure-Specific Patient Comfort Assessed by the Peripheral Intravenous Catheterization Comfort Scale (PIVCCS)
時間枠:Immediately after the catheterization procedure (within 30 minutes)
|
Procedure-specific patient comfort during peripheral intravenous catheterization, assessed with the 7-item Peripheral Intravenous Catheterization Comfort Scale (PIVCCS; Turkish version: PIKKO) rated on a 5-point Likert scale. Total scores range from 7 to 35, with higher scores indicating greater comfort. Self-reported by the patient after the procedure (T2). |
Immediately after the catheterization procedure (within 30 minutes)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Procedural Pain Intensity Assessed by Visual Analog Scale (VAS)
時間枠:Before the procedure (T0) and immediately after the catheterization procedure (T2, within 30 minutes)
|
Pain intensity assessed with a 10-cm Visual Analog Scale (VAS) (0 = no pain, 10 = unbearable pain), self-reported by the patient before (T0) and after (T2) the catheterization procedure. Post-procedure (T2) scores and the change from baseline (T2 minus T0) are compared between groups; pre- and post-procedure scores are compared within each group. |
Before the procedure (T0) and immediately after the catheterization procedure (T2, within 30 minutes)
|
|
First-Attempt Success Rate
時間枠:During the catheterization procedure (T1)
|
Proportion of patients in whom the peripheral intravenous catheter was successfully placed on the first attempt (yes/no). Success was defined as placement of the catheter in the vein from the first skin puncture without withdrawing the needle, free blood return in the catheter, no resistance when flushed with 10 mL of 0.9% NaCl and no signs of extravasation. Recorded by direct observation on a structured observation form. |
During the catheterization procedure (T1)
|
|
Total Number of Catheterization Attempts
時間枠:During the catheterization procedure (T1)
|
Total number of attempts needed for successful peripheral intravenous catheter placement, recorded as 1, 2, 3 or failed (maximum of three attempts allowed). An attempt was defined as the period from the first skin puncture until the needle was withdrawn from the skin or the catheter was successfully placed in the vein. Recorded by direct observation on a structured observation form. |
During the catheterization procedure (T1)
|
|
Total Procedure Duration
時間枠:During the catheterization procedure (T1)
|
Total duration of the catheterization procedure in seconds, measured with a digital stopwatch from tourniquet application to successful placement and fixation of the catheter. Recorded by direct observation on a structured observation form. |
During the catheterization procedure (T1)
|
|
Procedure-Related Complications
時間枠:During the catheterization procedure (T1)
|
Number and percentage of patients with procedure-related complications during catheterization: hematoma, extravasation and other adverse events during the procedure (each recorded as present/absent). Determined by the data collector through observation and questioning and recorded on a structured observation form. |
During the catheterization procedure (T1)
|
協力者と研究者
協力者
協力者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- B.30.2.ATA.0.01.00/596
- TDK-2025-16156 (その他の助成金/資金番号:Ataturk University Scientific Research Projects Coordination Unit (BAP))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data will not be shared in order to protect participant confidentiality. Study results will be reported in aggregate form in the doctoral thesis and related publications.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。